Role of Tyrosine Kinase Inhibition with Imatinib in an Encapsulating Peritoneal Sclerosis Rat Model

REFERENCES

• Balasubramaniam G, Brown EA, Davenport A, . The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant. 2009;24(10): 3209–3215.
   PubMed Web of Science ®Google Scholar
• Beyer C, Distler JH, Distler O. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Swiss Med Wkly. 2010;140:w13050, doi:10.4414/smw.2010.13050.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14): 1031–1037.
   PubMed Web of Science ®Google Scholar
• Daniels CE, Wilkes MC, Edens M, . Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004; 114(9):1308–1316.
   PubMed Web of Science ®Google Scholar
• Distler JH, Distler O. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis. 2010;69(Suppl. 1):i48–i51.
   PubMed Web of Science ®Google Scholar
• Akhmetshina A, Venalis P, Dees C, . Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009;60(1):219–224.
   PubMedGoogle Scholar
• Abdollahi A, Li M, Ping G, . Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med. 2005;201(6):925–935.
   PubMed Web of Science ®Google Scholar
• Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J. 2005;19(1):1–11.
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Noguchi R, Kuriyama S, . Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol. 2005;288(5):G907–G913.
   PubMed Web of Science ®Google Scholar
• Hoff CM. Experimental animal models of encapsulating peritoneal sclerosis. Perit Dial Int. 2005;25(Suppl. 4):S57–S66.
   Google Scholar
• Io H, Hamada C, Ro Y, . Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int. 2004;65:1927–1936.
   PubMed Web of Science ®Google Scholar
• Di Paolo N, Nicolai GA, Garosi G. The peritoneum: from histological studies to mesothelial transplant through animal experimentation. Perit Dial Int. 2008;28(Suppl. 5):S5–S9.
   Google Scholar
• Yu MA, Shin KS, Kim JH, . HGF and BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium. J Am Soc Nephrol. 2009;20(3):567–581.
   PubMed Web of Science ®Google Scholar
• Huang JW, Yen CJ, Wu HY, . Tamoxifen downregulates connective tissue growth factor to ameliorate peritoneal fibrosis. Blood Purif. 2011;31(4):252–258.
   PubMed Web of Science ®Google Scholar
• Ertilav M, Hur E, Bozkurt D, . Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis model. Nephrology (Carlton). 2011;16(6):552–557.
   PubMed Web of Science ®Google Scholar
• Bozkurt D, Bicak S, Sipahi S, . The effects of colchicine on the progression and regression of encapsulating peritoneal sclerosis. Perit Dial Int. 2008;28(Suppl. 5):S53–S57.
   PubMedGoogle Scholar
• Duman S, Bozkurt D, Sipahi S, . Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model. Adv Perit Dial. 2008;24: 104–110.
   PubMedGoogle Scholar
• Vittal R, Zhang H, Han MK, Moore BB, Horowitz JC, Thannickal VJ. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. J Pharmacol Exp Ther. 2007;321(1):35–44.
   PubMed Web of Science ®Google Scholar
• Strippoli R, Benedicto I, Perez Lozano/m L, . Inhibition of transforming growth factor-activated kinase 1 (TAK1) blocks and reverses epithelial to mesenchymal transition of mesothelial cells. PLoS One 2012;7(2):e31492.
   Web of Science ®Google Scholar
• Tejde M, Hadimeri H, Siegert CE, . Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int. 2009;29(6):647–655.
   PubMed Web of Science ®Google Scholar
• Yung S, Chan TM. Mesothelial cells. Perit Dial Int. 2007;27(Suppl. 2):S110– S115.
   PubMed Web of Science ®Google Scholar
• Lai KN, Lam MF, Leung JC. Peritoneal function: the role of aquaporins. Perit Dial Int. 2003;23(Suppl. 2):S20–S25.
   Google Scholar
• Liakopoulos V, Zarogiannis S, Hatzoglou C, . Inhibition by mercuric chloride of aquaporin-1 in the parietal sheep peritoneum: an electrophysiologic study. Adv Perit Dial. 2006;22: 7–10.
   PubMedGoogle Scholar
• Chaudhary NI, Roth GJ, Hilberg F, . Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29(5):976–985.
   PubMed Web of Science ®Google Scholar